NovMetaPharma Co., Ltd. (XKON:229500)
South Korea
· Delayed Price · Currency is KRW
13,720
+240 (1.78%)
At close: Dec 5, 2025
NovMetaPharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2014 | FY 2013 |
| Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 |
| Revenue | 1,295 | 1,068 |
| Revenue Growth (YoY) | 21.36% | - |
| Cost of Revenue | 683.23 | 534.68 |
| Gross Profit | 612.26 | 532.83 |
| Selling, General & Admin | 614.01 | 395.98 |
| Research & Development | 59.73 | 34.91 |
| Amortization of Goodwill & Intangibles | 24.18 | 24.01 |
| Other Operating Expenses | 15.11 | 20.64 |
| Operating Expenses | 735.64 | 484.82 |
| Operating Income | -123.38 | 48.01 |
| Interest & Investment Income | 9.3 | 0.6 |
| Currency Exchange Gain (Loss) | 24.15 | -29.08 |
| Other Non Operating Income (Expenses) | 80.65 | 0.08 |
| EBT Excluding Unusual Items | -9.27 | 19.62 |
| Gain (Loss) on Sale of Investments | 417.3 | - |
| Pretax Income | 408.03 | 19.62 |
| Net Income | 408.03 | 19.62 |
| Net Income to Common | 408.03 | 19.62 |
| Net Income Growth | 1979.47% | - |
| Shares Outstanding (Basic) | 3 | 3 |
| Shares Outstanding (Diluted) | 3 | 3 |
| Shares Change (YoY) | 21.30% | - |
| EPS (Basic) | 120.00 | 7.00 |
| EPS (Diluted) | 120.00 | 7.00 |
| EPS Growth | 1614.28% | - |
| Free Cash Flow | -263.81 | 164.26 |
| Free Cash Flow Per Share | -77.58 | 58.60 |
| Gross Margin | 47.26% | 49.91% |
| Operating Margin | -9.52% | 4.50% |
| Profit Margin | 31.50% | 1.84% |
| Free Cash Flow Margin | -20.36% | 15.39% |
| EBITDA | -75.2 | 79.9 |
| EBITDA Margin | -5.80% | 7.48% |
| D&A For EBITDA | 48.18 | 31.88 |
| EBIT | -123.38 | 48.01 |
| EBIT Margin | -9.52% | 4.50% |
| Advertising Expenses | 29.58 | 3 |
Source: S&P Capital IQ. Standard template.
Financial Sources.